SynthesisBMC nephrology2026
Risk factors for acute kidney injury in Chinese patients with lupus nephritis: a meta-analysis.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere exists a significant population of lupus nephritis (LN) patients in China, and acute kidney injury (AKI) represents the prevalent complication associated with LN. Our study is aimed at investigating the risk factors for AKI in Chinese patients with LN through a meta-analysis.
methodsA comprehensive literature search was performed using PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wangfang, VIP, and SinoMed, encompassing studies from the inception of each database through January 2024. EndNote v20.0 was employed for reference management, Newcastle-Ottawa Scale was utilized for quality assessment. R v4.3.2 was used for data analysis and visualization. Subgroup analysis, sensitivity analysis, and publication bias evaluation were carried out to verify the robustness of the results.
resultsNineteen articles were included in our study, comprising 4305 patients, 1434 in the AKI group and 2871 in the no-AKI group. Male (OR = 1.43, 95% CI: 1.08–1.88), infection (OR = 3.35, 95% CI: 2.37–4.74), hypertension (OR = 1.27, 95% CI: 1.04, 1.56), serositis, positive for SSB antibody (OR = 1.54, 95% CI: 1.17–2.04), and renal pathology type IV (OR = 3.81, 95% CI: 2.43–5.98) were identified as risk factors for AKI in patients with LN. Additionally, high disease activity and markers of systemic damage were associated with increased risk of AKI, including hematuria (OR = 2.01, 95% CI: 1.21–3.25), anemia(OR = 2.65, 95% CI: 1.86–3.79), high 24-hour U-Pro levels (MD = 1.81, 95% CI: 1.10–2.52), positive for ds-DNA antibody (OR = 1.70, 95% CI: 1.41–2.07), and high SLEDAI (MD = 3.09, 95% CI: 2.01–4.16). Low disease activity characterized by high serum albumin levels and high C3 levels decreased risk of AKI. While there were differences from the studies, their impact on the results was minimal, and no significant publication bias was detected.
conclusionThe risk factors for AKI in patients with LN were evaluated in this research, and data support was provided for clinical risk assessment. To facilitate personalized diagnosis and treatment for patients with multiple risk factors simultaneously and optimize therapeutic measures for protecting kidney function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.